Enhanced Genomics Secures €16 Million To Accelerate Therapeutics Pipeline Development

This brings its total Series A funding to €16 million, with support from investors BGF, Parkwalk and Meltwind.

“Our Founders have led the field by developing technology to map 3D interactions on a whole-genome scale, and integrating these data with comprehensive multi-omics datasets. We now have the technological capabilities to decipher the causal biology that drives complex and common genetic diseases, with the potential to develop truly effective new blockbuster therapies.” said Dietrich A. Stephan, Ph.D., Chair, Enhanced Genomics.

Founded in 2020, Enhanced Genomics positions itself as the only biotech company capable of defining causal biology from disease-associated variants on a genome-wide scale. This enables the rapid discovery of high-confidence, first-in-class therapeutic targets for common diseases with blockbuster potential.

Read Also - Amsterdam-Based Sympower Secures €42M To Advance Europe’s Energy Transition

By leveraging decades of genetic data and its proprietary 3D multi-omics platform, along with a detailed human cell type-specific atlas, Enhanced Genomics accelerates drug discovery and precision medicine.

Its 3D multi-omics platform is a genome-wide, hypothesis-free technology that translates vast disease-variant data into causal biology at a cell-type-specific level. This approach enhances target prioritization—more than doubling the probability of success—and dramatically increases the identification of novel disease targets, all in a fraction of the usual time.

Additionally, the platform enables patient stratification into responder groups, streamlining and improving the efficiency of clinical trials.

“This puts us in a strong position to lead the next major shift in pharma. When developing a novel approach to drug discovery, clarity of thought and courage are required to build deep conviction, and we are proud to have built a team that embodies this. We thank our investors for continuing to support our vision,” added Stephan.

The funding will support the expansion of Enhanced Genomics’ internal therapeutic pipeline for common diseases, including autoimmune disorders like inflammatory bowel disease. This investment will allow the company to scale its efforts through strategic collaborations with pharma and biotech partners, capitalizing on novel target identification and asset-driven opportunities to fuel long-term growth.

By converting vast amounts of disease-associated data into actionable insights, Enhanced identifies high-confidence targets with strong genetic evidence of causality. This approach significantly boosts the likelihood of success in drug development while reducing the time and cost typically required.

About Enhanced Genomics

Enhanced Genomics is a leading functional genomics company using proprietary 3D multi-omics technology to revolutionize drug target discovery. By integrating 3D genomics with multi-omics the company uncovers precise gene regulation and disease mechanisms, accelerating the identification of novel therapeutic targets and enabling faster development of treatments across diverse disease areas.